Voyager TherapeuticsVYGR
VYGR
About: Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Employees: 162
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
28% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 18
19% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 37
1% more funds holding
Funds holding: 128 [Q3] → 129 (+1) [Q4]
1.76% less ownership
Funds ownership: 64.92% [Q3] → 63.16% (-1.76%) [Q4]
6% less capital invested
Capital invested by funds: $207M [Q3] → $196M (-$11.9M) [Q4]
42% less call options, than puts
Call options by funds: $273K | Put options by funds: $474K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5.73
36%
upside
Avg. target
$15.91
277%
upside
High target
$30
611%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Patrick Trucchio 43% 1-year accuracy 76 / 175 met price target | 611%upside $30 | Buy Reiterated | 27 Jan 2025 |
Cantor Fitzgerald Pete Stavropoulos 14% 1-year accuracy 3 / 22 met price target | 36%upside $5.73 | Overweight Initiated | 10 Jan 2025 |
Citigroup Samantha Semenkow 29% 1-year accuracy 4 / 14 met price target | 184%upside $12 | Buy Initiated | 2 Dec 2024 |
Financial journalist opinion
Based on 22 articles about VYGR published over the past 30 days
Neutral
PRNewsWire
9 hours ago
VYGR Investors Have Opportunity to Join Voyager Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES , Feb. 21, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ: VYGR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
20 hours ago
Levi & Korsinsky Reminds Voyager Therapeutics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - VYGR
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Voyager Therapeutics, Inc. ("Voyager Therapeutics, Inc.") (NASDAQ:VYGR) concerning possible violations of federal securities laws. Voyager issued a press release on February 11, 2025, "announc[ing] it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)", stating that "[e]merging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting in a narrowed therapeutic window.
Neutral
Accesswire
21 hours ago
An Investigation Has Been Launched Into Voyager Therapeutics, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / February 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ:VYGR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
21 hours ago
Voyager Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - VYGR
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Voyager Therapeutics, Inc. ("Voyager Therapeutics, Inc.") (NASDAQ:VYGR) concerning possible violations of federal securities laws. Voyager issued a press release on February 11, 2025, "announc[ing] it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)", stating that "[e]merging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting in a narrowed therapeutic window.
Neutral
Accesswire
22 hours ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
NEW YORK CITY, NY / ACCESS Newswire / February 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ:VYGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
Accesswire
1 day ago
Lost Money on Voyager Therapeutics, Inc. (VYGR)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Voyager Therapeutics, Inc. ("Voyager Therapeutics, Inc.") (NASDAQ:VYGR) concerning possible violations of federal securities laws. Voyager issued a press release on February 11, 2025, "announc[ing] it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)", stating that "[e]merging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting in a narrowed therapeutic window.
Neutral
Accesswire
1 day ago
The Schall Law Firm Invites Shareholders With Losses In Voyager Therapeutics, Inc. To Join A Securities Fraud Investigation
LOS ANGELES, CA / ACCESS Newswire / February 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NASDAQ:VYGR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Business Wire
1 day ago
VYGR Investors Have Opportunity to Join Voyager Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--VYGR Investors Have Opportunity to Join Voyager Therapeutics, Inc. Fraud Investigation with the Schall Law Firm.
Neutral
Accesswire
2 days ago
Investors who Lost Money on Voyager Therapeutics, Inc. Should Contact Levi & Korsinsky about an Ongoing Investigation - VYGR
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Voyager Therapeutics, Inc. ("Voyager Therapeutics, Inc.") (NASDAQ:VYGR) concerning possible violations of federal securities laws. Voyager issued a press release on February 11, 2025, "announc[ing] it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)", stating that "[e]merging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting in a narrowed therapeutic window.
Neutral
GlobeNewsWire
2 days ago
Kirby McInerney LLP Announces Investigation Against Voyager Therapeutics, Inc. (VYGR) on Behalf of Investors
NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Voyager Therapeutics, Inc. (“Voyager” or the “Company”) (NASDAQ:VYGR). The investigation concerns whether Voyager and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
Charts implemented using Lightweight Charts™